Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology

Annals of Oncology

Volumn 11, Issue 12, 2000, Pages 1591-1595

  Knox, K S ^a   Adams, J R ^a   Djulbegovic, B ^b   Stinson, T J ^a   Tomori, C ^a   Bennett, C L ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cost effectiveness; Economic analyses; Pharmaceutical sponsorship

Indexed keywords

ANTIEMETIC AGENT; COLONY STIMULATING FACTOR RECEPTOR; HEMOPOIETIC GROWTH FACTOR; SEROTONIN ANTAGONIST; TAXANE DERIVATIVE;

ANALYTIC METHOD; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; ECONOMIC ASPECT; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 0034488410     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008309817708     Document Type: Article

References (28)

1. Health care CBA and CEA from 1991 to 1996: An updated bibliography
2. Quality assessment of economic evaluations in selected pharmacy, medical, and health economics journals
3. Cost-effectiveness and cost-benefit analyses in the medical literature
4. Economic analysis in randomized control trials
5. Interpretation of 'cost-effective' and soundness of economic evaluations in the pharmacy literature
6. Economic evaluations in the critical care literature: Do they help us improve the efficiency of our unit?
7. Quality assessment of pharmacoeconomic abstracts of original research articles in selected journals
8. Quality assessment of economic evaluations published in PharmacoEconomics
9. Evaluation of pharmacoeconomic studies: Utilization of a checklist
10. Evaluating the BMJ guidelines for economic submissions
11. Influences on the quality of published drug studies
12. Source of funding and outcome of clinical trials
13. Problems in the design and reporting of trials of antifungal agents encountered during metaanalysis
14. The uncertainty principle and industry-sponsored research
15. The effectiveness of cost-effectiveness analysis in containing costs
16. Evaluation of conflict of interest in economic analyses of new drugs used in oncology
17. Drug-Firm Backed Studies Are Tied to Positive Results
18. Developing guidelines for pharmacoeconomic trials
19. The role of cost-effectiveness analysis in health and medicine
20. Recommendations of the panel on cost-effectivenss in health and medicine
21. Recommendations for reporting cost-effectiveness analyses
22. The quality of drug studies published in symmposium proceedings
23. Conflict of interest and cost-effectiveness analysis
24. Free-riding and the prisoners dilemma: Problems in funding economic analysis of phase III cancer clinical trials
25. Under-reporting research is scientific misconduct
26. Time to register randomized trials (Editorial)
27. How important is publication bias? A synthesis of available data
28. Publication Bias: The case for an international registry of clinical trials